This study aimed to examine the amount of surface non-specific adsorption, or fouling, observed by Pseudomonas aeruginosa (P. aeruginosa) on a quartz crystal based acoustic wave biosensor under different flow conditions with and without an anti-fouling layer.
An electromagnetic piezoelectric acoustic sensor (EMPAS) based on electrode free quartz crystals was used to perform the analysis. Phosphate buffered saline (PBS) was flowed over the crystal surface at various flow rates from 50 μL/min to 200 μL/min, with measurements being taken at the 43rd harmonic (~864 MHz). The crystal was either unmodified, or modified with a monoethylene glycol [2-(3-silylpropyloxy)-hydroxy-ethyl (MEG-OH)] anti-fouling layer. Overnight culture of P. aeruginosa PAO1 (PAO1) in lysogeny broth (LB) was injected into the system, and flow maintained for 30 min.
The frequency change of the EMPAS crystal after injection of bacteria into the system was found to change based on the flow rate of buffer, suggesting the flow rate has a strong effect on the level of non-specific adsorption. The MEG-OH layer drastically reduced the level of fouling observed under all flow conditions, as well as reduced the amount of variation between experiments. Flow rates of 150 μL/min or higher were found to best reduce the level of fouling observed as well as experimental variation.
The MEG-OH anti-fouling layer is important for accurate and reproducible biosensing measurements due to the reduced fouling and variation during experiments. Additionally, a flow rate of 150 μL/min may prove better for measurement compared to the current standard of 50 μL/min for this type of instrument.
This study aims to discover an alternative precursor with abundant source and low cost for multicolor graphene quantum dots (GQDs) preparation and application.
In the current study, anthracite-derived multicolor GQDs were prepared at different reaction temperatures (100°–150°C), referring to the GQDs 100, GQDs 120, GQDs 130, and GQDs 150.
The GQDs 100, GQDs 120, GQDs 130, and GQDs 150 solutions were found to be orange-red, yellow-green, green, and blue under 365 nm excitation UV (ultraviolet) lamp, respectively. The X-ray photoelectron spectroscopy (XPS) data suggests high temperature intensifies oxidation of the amorphous sp3 carbon, resulting in GQDs with higher crystalline structure (Csp2). Compared with the GQDs 100 and GQDs 120, the GQDs 130 and GQDs 150 showed much better biocompatibility, which may attribute to their higher Csp2 composition and smaller size.
The results suggest that GQDs 130 and GQDs 150 are ideal candidates for nanomedicine applications, e.g., drug/gene delivery and bio-imaging, etc.
Translating biomaterials research into clinical products is a multidisciplinary yet rewarding journey. It should primarily aim to improve patient treatment and clinical outcomes by addressing unmet clinical needs. Four examples of commercial development of biomaterial implants illustrate the diversity of paths, starting from academic research work (AlchiMedics, TISSIUM, Cousin Surgery) or corporate initiatives to develop new products (Medtronic-Sofradim Production). They have been selected from the Translational Research session of the 2022 Conference of the European Society for Biomaterials (ESB) in Bordeaux (France). Commitment, agility, and perseverance were among the key common skills to successfully meet challenges, especially the most unexpected ones. All dimensions of translation projects must be integrated from the start, including the regulatory strategy.
[Names] => Yves Bayon ... Didier Letourneur [CName] => [Doi] => 10.37349/ebmx.2024.00004 [Published] => January 16, 2024 [Viewed] => 890 [Downloaded] => 51 [Subject] => Review [Year] => 2024 [CiteUrl] => https://api.crossref.org/works/10.37349/ebmx.2023.00004 [Inline] => 1 [Type] => 1 [Issue] => 1 [Topic] => 0 [TitleAbbr] => Explor BioMat-X. [Pages] => 2024;1:23–33 [Recommend] => 0 [Keywords] => Biomaterials, medical devices, translation, clinical development [DetailTitle] => [DetailUrl] => [Id] => 10134 [ris] => https://www.explorationpub.com/uploads/Article/A10134/982e8fba1fc319049b95ceddaef28a8a.ris [bib] => https://www.explorationpub.com/uploads/Article/A10134/b3dbbc6cecc5a465759c626a22c53321.bib [ens] => [Cited] => 0 [Cited_Time] => [CitethisArticle] => Bayon Y, Bureau C, Perreira M, Aubert F, Caillibotte M, Vestberg R, et al. Journey of medical device development from the bench to the bedside—four real-life examples of commercial biomaterials development. Explor BioMat-X. 2024;1:23–33. https://doi.org/10.37349/ebmx.2024.00004 [Jindex] => 0 [CEmail] => [Ris_Time] => 2024-01-16 01:17:48 [Bib_Time] => 2024-01-16 01:17:48 [KeysWordContens] => Journey of medical device development from the bench to the bedside—four real-life examples of commercial biomaterials development, Biomaterials, medical devices, translation, clinical development, Translating biomaterials research into clinical products is a multidisciplinary yet rewarding journey. It should primarily aim to improve patient treatment and clinical outcomes by addressing unmet clinical needs. Four examples of commercial development of biomaterial implants illustrate the diversity of paths, starting from academic research work (AlchiMedics, TISSIUM, Cousin Surgery) or corporate initiatives to develop new products (Medtronic-Sofradim Production). They have been selected from the Translational Research session of the 2022 Conference of the European Society for Biomaterials (ESB) in Bordeaux (France). Commitment, agility, and perseverance were among the key common skills to successfully meet challenges, especially the most unexpected ones. All dimensions of translation projects must be integrated from the start, including the regulatory strategy. ,Yves Bayon ... Didier Letourneur [PublishedText] => Published [IsEdit] => 0 [AccountId] => 88 [Zh] => 1 [AuthorsName] => Yves Bayon, Christophe Bureau, Maria J N Perreira, François Aubert, Michel Caillibotte, Robert Vestberg, Didier Letourneur ) [4] => Array ( [ArticleId] => 1142 [Create_Time] => 2024-02-26 [zipUrl] => https://www.explorationpub.com/uploads/zip/202402/20240226104234.zip [xmlUrl] => https://www.explorationpub.com/uploads/Article/A10135/10135.xml [pdfUrl] => https://www.explorationpub.com/uploads/Article/A10135/10135.pdf [coverUrl] => https://www.explorationpub.com/uploads/Article/A10135/10135_cover.png [JournalsId] => 13 [Title] => Fabrication and characterization of pHEMA hydrogel conduit containing GelMA-HaMA IPN for peripheral nerve regeneration [Abstract] => Aim: Small defects after any injury to the periperal nerves results in self-regeneration. However, for larger defects, suturing or grafting are necessary, which may have limitations. Thus, resear [AbstractComplete] =>Small defects after any injury to the periperal nerves results in self-regeneration. However, for larger defects, suturing or grafting are necessary, which may have limitations. Thus, research on nerve guidence conduits is needed without drawbacks. The aim of the study was to develop hydrogel-based conduits containing interpenetrating network (IPN).
Methacrylated gelatin (GelMA)-methacrylated hyaluronic acid (HaMA) IPN was filled the poly(2-hydroxyethylmethacrylate) (pHEMA) the outer conduit. Schwann cells (SCs) were used on the pHEMA and the distal end of the tube was injected with netrin-1 to support model SH-SY5Y cells.
1H-nuclear magnetic resonance (1H-NMR) showed that methacrylation degrees were 94% ± 2% for GelMA and 60% ± 7% for HaMA. The fraction of HaMA increased the degradation rate; pure HaMA degraded in 3 weeks, while pure GelMA in more than 5 weeks. An increase in the fraction of 2-hydroxyethylmethacrylate (HEMA) from 20% to 56% decreased the porosity and the pore size, significantly. SH-SY5Y cells migrated along the conduit in the presence of netrin-1. NeuN expression was increased in 2 weeks indicating neuronal activity.
SH-SY5Y cells produced neurites in the IPN. pHEMA conduit including GelMA-HaMA IPN is a good candidate for peripheral nerve regeneration applications. As future studies, the conduit will be tested in vivo for nerve regeneration.
The pleiotropic effect of fibroblast growth factor 2 (FGF2) on promoting myogenesis, angiogenesis, and innervation makes it an ideal growth factor for treating volumetric muscle loss (VML) injuries. While an initial delivery of FGF2 has demonstrated enhanced regenerative potential, the sustained delivery of FGF2 from scaffolds with robust structural properties as well as biophysical and biochemical signaling cues has yet to be explored for treating VML. The goal of this study is to develop an instructive fibrin microthread scaffold with intrinsic topographic alignment cues as well as regenerative signaling cues and a physiologically relevant, sustained release of FGF2 to direct myogenesis and ultimately enhance functional muscle regeneration.
Heparin was passively adsorbed or carbodiimide-conjugated to microthreads, creating a biomimetic binding strategy, mimicking FGF2 sequestration in the extracellular matrix (ECM). It was also evaluated whether FGF2 incorporated into fibrin microthreads would yield sustained release. It was hypothesized that heparin-conjugated and co-incorporated (co-inc) fibrin microthreads would facilitate sustained release of FGF2 from the scaffold and enhance in vitro myoblast proliferation and outgrowth.
Toluidine blue staining and Fourier transform infrared spectroscopy confirmed that carbodiimide-conjugated heparin bound to fibrin microthreads in a dose-dependent manner. Release kinetics revealed that heparin-conjugated fibrin microthreads exhibited sustained release of FGF2 over a period of one week. An in vitro assay demonstrated that FGF2 released from microthreads remained bioactive, stimulating myoblast proliferation over four days. Finally, a cellular outgrowth assay suggests that FGF2 promotes increased outgrowth onto microthreads.
It was anticipated that the combined effects of fibrin microthread structural properties, topographic alignment cues, and FGF2 release profiles will facilitate the fabrication of a biomimetic scaffold that enhances the regeneration of functional muscle tissue for the treatment of VML injuries.
Since decades, decellularized extracellular matrix (dECM)-derived materials have received worldwide attention as promising biomaterials for tissue engineering and biomedical applications. Soluble dECM is a versatile raw material that can be easily engineered into the desired shapes and structures. However, there are still some limitations restricting its use, including low hydrophilicity and smooth surfaces, which negatively influence cell adhesion/spreading. The objective of the present study was to investigate surface modification by nitrogen/hydrogen (N2/H2) low-pressure cold plasma treatment as a potential technique to improve the biological response of bovine pericardium dECM films.
Bovine pericardium dECM was enzymatically digested and lyophilized prior to the preparation of thin films via solvent-casting method. Changes in surface properties after plasma treatment were investigated using water contact angle (WCA) and X-ray photoelectron spectroscopy (XPS) measurements. Immunofluorescence staining and resazurin assay for human dermal fibroblasts (HDFs) cultured on the dECM films were used to assess the bioactivity of dECM films. Finally, the hemocompatibility of the films was investigated via clotting time and hemolysis assay.
WCA and XPS results revealed that oxygen (O)- and N-containing functional groups were incorporated onto the film surface and an increase in hydrophilicity was observed after plasma treatment. In vitro experiments showed that cell adhesion in plasma-treated dECM films is much faster if compared to the untreated controls. Moreover, the fibroblast proliferation increased after plasma surface modifications. Finally, the hemocompatibility analysis results indicated a delayed blood clotting and no hemolytic effects for all the tested samples.
These findings confirmed the potential of dECM as raw material for biocompatible thin films fabrication. Additionally, plasma surface treatment emerged as an eco-friendly and cost-effective strategy to enhance in vitro cell attachment and proliferation on dECM films, expanding their applications in biomedicine.
Neurodegenerative diseases (NDDs) gradually affect neurons impacting both their function and structure, and they afflict millions worldwide. Detecting these conditions before symptoms arise is crucial for better prognosis and duality of life, given that the disease processes often begin years earlier. Yet, reliable and affordable methods to diagnose NDDs in these stages are currently lacking. There’s a growing interest in using circulating extracellular vesicles (EVs), like small EVs (sEVs) also known as exosomes, as potential sources of markers for screening, diagnosing, and monitoring NDDs. This interest stems from evidence showing that these EVs can carry brain pathological proteins implicated in NDD pathology, and they can even traverse the blood-brain barrier. This review focuses on the creation of EVs, particularly sEVs with a size of less than 200 nanometers, methods for isolating sEVs, and recent advancements in biosensor development to detect NDD-related markers found in sEVs. Furthermore, it explores the potential of sEVs in diagnosing four major NDDs: Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and multiple system atrophy (MSA).
[Names] => Saqer Al Abdullah ... Kristen Dellinger [CName] => [Doi] => 10.37349/ebmx.2024.00008 [Published] => April 24, 2024 [Viewed] => 687 [Downloaded] => 32 [Subject] => Review [Year] => 2024 [CiteUrl] => https://api.crossref.org/works/10.37349/ebmx.2024.00008 [Inline] => 1 [Type] => 1 [Issue] => 2 [Topic] => 0 [TitleAbbr] => Explor BioMat-X. [Pages] => 2024;1:100–123 [Recommend] => 0 [Keywords] => Exosomes, biosensing, Alzheimer’s disease, Parkinson’s disease [DetailTitle] => [DetailUrl] => [Id] => 10138 [ris] => https://www.explorationpub.com/uploads/Article/A10138/abd8dd0a14950c1564157f88365ade8c.ris [bib] => https://www.explorationpub.com/uploads/Article/A10138/96d707993266befe45c2ca3239f8412f.bib [ens] => [Cited] => 0 [Cited_Time] => [CitethisArticle] => Al Abdullah S, Cocklereece I, Dellinger K. Unlocking the potential of circulating small extracellular vesicles in neurodegenerative disease through targeted biomarkers and advancements in biosensing. Explor BioMat-X. 2024;1:100–23. https://doi.org/10.37349/ebmx.2024.00008 [Jindex] => 0 [CEmail] => [Ris_Time] => 2024-04-16 00:57:01 [Bib_Time] => 2024-04-16 00:57:01 [KeysWordContens] => Unlocking the potential of circulating small extracellular vesicles in neurodegenerative disease through targeted biomarkers and advancements in biosensing, Exosomes, biosensing, Alzheimer’s disease, Parkinson’s disease, Neurodegenerative diseases (NDDs) gradually affect neurons impacting both their function and structure, and they afflict millions worldwide. Detecting these conditions before symptoms arise is crucial for better prognosis and duality of life, given that the disease processes often begin years earlier. Yet, reliable and affordable methods to diagnose NDDs in these stages are currently lacking. There’s a growing interest in using circulating extracellular vesicles (EVs), like small EVs (sEVs) also known as exosomes, as potential sources of markers for screening, diagnosing, and monitoring NDDs. This interest stems from evidence showing that these EVs can carry brain pathological proteins implicated in NDD pathology, and they can even traverse the blood-brain barrier. This review focuses on the creation of EVs, particularly sEVs with a size of less than 200 nanometers, methods for isolating sEVs, and recent advancements in biosensor development to detect NDD-related markers found in sEVs. Furthermore, it explores the potential of sEVs in diagnosing four major NDDs: Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and multiple system atrophy (MSA). ,Saqer Al Abdullah ... Kristen Dellinger [PublishedText] => Published [IsEdit] => 0 [AccountId] => 76 [Zh] => 0 [AuthorsName] => Saqer Al Abdullah, Ivy Cocklereece, Kristen Dellinger ) [8] => Array ( [ArticleId] => 1247 [Create_Time] => 2024-04-26 [zipUrl] => https://www.explorationpub.com/uploads/zip/202404/20240426003425.zip [xmlUrl] => https://www.explorationpub.com/uploads/Article/A10139/10139.xml [pdfUrl] => https://www.explorationpub.com/uploads/Article/A10139/10139.pdf [coverUrl] => https://www.explorationpub.com/uploads/Article/A10139/10139-cover.png [JournalsId] => 13 [Title] => Navigating regulatory challenges in molecularly tailored nanomedicine [Abstract] => Nanomedicine, a convergence of nanotechnology and medical sciences, has unleashed transformative potential in healthcare. However, harnessing the benefits of nanomedicine requires a thorough underst [AbstractComplete] =>Nanomedicine, a convergence of nanotechnology and medical sciences, has unleashed transformative potential in healthcare. However, harnessing the benefits of nanomedicine requires a thorough understanding of its regulatory landscape. An in-depth discussion of regulatory considerations, including molecular safety assessment, harmonization of the regulatory landscape, and shaping the future of innovation, is presented in this discourse. The molecular safety assessment entails evaluating interactions between nanoparticles and biomolecules, ensuring compatibility at the molecular level. Harmonization involves developing international standards and guidelines for a consistent regulatory approach, while shaping innovations emphasizes integrating molecular safety assessments into early stages of development. Challenges encompass the need for standardized assessment methods, balancing innovation with safety, and addressing unique features of novel molecular designs. As the nanomedicine landscape evolves, effective regulatory strategies must navigate the intricate interplay of molecules and technologies, ensuring both patient access and product safety.
[Names] => Ajay Vikram Singh ... Paolo Zamboni [CName] => [Doi] => 10.37349/ebmx.2024.00009 [Published] => April 25, 2024 [Viewed] => 773 [Downloaded] => 62 [Subject] => Commentary [Year] => 2024 [CiteUrl] => https://api.crossref.org/works/10.37349/ebmx.2024.00009 [Inline] => 1 [Type] => 1 [Issue] => 2 [Topic] => 0 [TitleAbbr] => Explor BioMat-X. [Pages] => 2024;1:124–134 [Recommend] => 0 [Keywords] => Nanomedicine, regulatory considerations, molecular safety assessment, harmonization, innovations, patient safety [DetailTitle] => [DetailUrl] => [Id] => 10139 [ris] => https://www.explorationpub.com/uploads/Article/A10139/a48d98fea657c48520c3b7369796403b.ris [bib] => https://www.explorationpub.com/uploads/Article/A10139/271f56d4e1205f2e2f0b14a2f62ec760.bib [ens] => [Cited] => 2 [Cited_Time] => 2024-07-21 [CitethisArticle] => Singh AV, Bhardwaj P, Upadhyay AK, Pagani A, Upadhyay J, Bhadra J, et al. Navigating regulatory challenges in molecularly tailored nanomedicine. Explor BioMat-X. 2024;1:124–34. https://doi.org/10.37349/ebmx.2024.00009 [Jindex] => 0 [CEmail] => [Ris_Time] => 2024-04-25 08:15:31 [Bib_Time] => 2024-04-17 03:21:16 [KeysWordContens] => Navigating regulatory challenges in molecularly tailored nanomedicine, Nanomedicine, regulatory considerations, molecular safety assessment, harmonization, innovations, patient safety, Nanomedicine, a convergence of nanotechnology and medical sciences, has unleashed transformative potential in healthcare. However, harnessing the benefits of nanomedicine requires a thorough understanding of its regulatory landscape. An in-depth discussion of regulatory considerations, including molecular safety assessment, harmonization of the regulatory landscape, and shaping the future of innovation, is presented in this discourse. The molecular safety assessment entails evaluating interactions between nanoparticles and biomolecules, ensuring compatibility at the molecular level. Harmonization involves developing international standards and guidelines for a consistent regulatory approach, while shaping innovations emphasizes integrating molecular safety assessments into early stages of development. Challenges encompass the need for standardized assessment methods, balancing innovation with safety, and addressing unique features of novel molecular designs. As the nanomedicine landscape evolves, effective regulatory strategies must navigate the intricate interplay of molecules and technologies, ensuring both patient access and product safety. ,Ajay Vikram Singh ... Paolo Zamboni [PublishedText] => Published [IsEdit] => 0 [AccountId] => 76 [Zh] => 0 [AuthorsName] => Ajay Vikram Singh, Preeti Bhardwaj, Aditya Kumar Upadhyay, Anselmo Pagani, Jyoti Upadhyay, Jolly Bhadra, Veronica Tisato, Manali Thakur, Donato Gemmati, Rudresh Mishra, Paolo Zamboni ) [9] => Array ( [ArticleId] => 1260 [Create_Time] => 2024-04-28 [zipUrl] => https://www.explorationpub.com/uploads/zip/202404/20240428061615.zip [xmlUrl] => https://www.explorationpub.com/uploads/Article/A101310/101310.xml [pdfUrl] => https://www.explorationpub.com/uploads/Article/A101310/101310.pdf [coverUrl] => https://www.explorationpub.com/uploads/Article/A101310/101310_cover.png [JournalsId] => 13 [Title] => Nanoparticle-functionalized acrylic bone cement for local therapeutic delivery to spine metastases [Abstract] => Aim: Polymethylmethacrylate bone cement is often used to reconstruct critical-sized defects generated by the surgical resection of spinal metastases. Residual tumor cells after a resection can dr [AbstractComplete] =>Polymethylmethacrylate bone cement is often used to reconstruct critical-sized defects generated by the surgical resection of spinal metastases. Residual tumor cells after a resection can drive recurrence and destabilization. Doxorubicin (DOX) is a common chemotherapeutic drug with unwanted side-effects when administered systemically. Mesoporous silica nanoparticles (NPs) are gaining attention for targeted drug delivery to bypass the negative side effects associated with systemic drug administration. An NP-functionalized cement was developed for the local release of DOX and its ability to suppress cancer cells was tested.
DOX was loaded onto NPs which were then mixed into the cement. Static contact angles were measured. Drug release profiles were obtained over a period of 4 weeks. Cement constructs were incubated with two-dimensional (2D) cultures of human bone-marrow derived mesenchymal stem cells and human osteoblasts, as well as 2D and three-dimensional (3D) cultures of breast and prostate cancer cell lines. Cell metabolic activity and viability were evaluated. Cell migration and spheroid growth of cancer cell lines were assessed in collagen-coated spheroid cultures.
NPs were homogenously dispersed and did not alter the mechanical strength nor the wettability of the cement. A sustained DOX release profile was achieved with the addition of NPs to the bone cement. The release profile of DOX from NP cement may be modified by varying the amount of the drug loaded onto the NPs and the proportion of NPs in the cement. Cancer cells treated with the cement constructs showed a dose- and time-dependent inhibition, with minimal toxicity against healthy cells. Cancer cell migration and spheroid growth were impaired in 3D culture.
NPs were shown to be essential for sustained DOX release from bone cement. DOX-loaded NP cement can inhibit cancer cells and impair their migration, with strong potential for in vivo translation studies.
The use of autologous cartilage and bone grafts remains the gold standard in augmentation rhinoplasty performed to reconstruct of the nasal dorsum. Meanwhile, limited number of available sources, donor site morbidity, and unpredictable graft resorption represent significant disadvantages of autografting. The aim of this study is to test combination of autologous stromal vascular fraction (SVF) and commercially available bone substitutes (BSs) as new tissue-engineered grafting material (GM) for rhinoplasty. A series of consecutive cases includes four adult patients who underwent rhinoplasty to correct saddle nose deformity (SND) using the new graft technique. SVF was isolated from liposuction aspirate using standard methodology of enzymatic digestion. Two types of BSs were combined with SVF: Bio-Oss granules to create a moldable graft (M-graft), and block-shaped BoneMedik-S to create rigid grafts (R-grafts). The moderate SND was treated using an M-graft. In case of major or complex SND, the nasal dorsum was reconstructed with dorso-columellar L-shaped framework made of R-grafts. The results were evaluated over a period of 6 months to 3 years postoperatively using photogrammetry and FACE-Q appearance appraisal scales. Computerised tomography (CT) scanning of the reconstructed nose and histological analysis of grafted material were also carried out. No complications were observed. The photograms show the restoration of the correct contour of the nose. FACE-Q appraisal scale scores increased significantly, including satisfaction with nose appearance, psychological well-being, and social function. In CT evaluation, there was no substantial resorption or warping of the grafts. Histological findings show osteogenic remodeling of the grafted material. Thus, combining autologous SVF with BSs is a promising strategy for developing rhinoplasty GM.
[Names] => Vladimir Karpiuk ... Olga Ponkina [CName] => [Doi] => 10.37349/ebmx.2024.00011 [Published] => June 03, 2024 [Viewed] => 402 [Downloaded] => 20 [Subject] => Case Report [Year] => 2024 [CiteUrl] => https://api.crossref.org/works/10.37349/ebmx.2024.00011 [Inline] => 1 [Type] => 1 [Issue] => 3 [Topic] => 200 [TitleAbbr] => Explor BioMat-X. [Pages] => 2024;1:158–173 [Recommend] => 0 [Keywords] => Augmentation rhinoplasty, saddle nose deformity, tissue-engineered bone grafts, stromal vascular fraction [DetailTitle] => Bioinspired Material for Regenerative Medicine [DetailUrl] => https://www.explorationpub.com/Journals/ebmx/Special_Issues/200 [Id] => 101311 [ris] => https://www.explorationpub.com/uploads/Article/A101311/46639cc95855b6d0ebc6483f6fb69eee.ris [bib] => https://www.explorationpub.com/uploads/Article/A101311/7229ec4532eee8deb06864dc9a2d5ff3.bib [ens] => [Cited] => 0 [Cited_Time] => [CitethisArticle] => Karpiuk V, Gilevich I, Perova M, Ponkina O. Tissue engineering approach to the creation of grafting material for rhinoplasty: clinical case reports. Explor BioMat-X. 2024;1:158–73. https://doi.org/10.37349/ebmx.2024.00011 [Jindex] => 0 [CEmail] => [Ris_Time] => 2024-06-28 03:42:25 [Bib_Time] => 2024-06-28 03:42:25 [KeysWordContens] => Tissue engineering approach to the creation of grafting material for rhinoplasty: clinical case reports, Augmentation rhinoplasty, saddle nose deformity, tissue-engineered bone grafts, stromal vascular fraction, The use of autologous cartilage and bone grafts remains the gold standard in augmentation rhinoplasty performed to reconstruct of the nasal dorsum. Meanwhile, limited number of available sources, donor site morbidity, and unpredictable graft resorption represent significant disadvantages of autografting. The aim of this study is to test combination of autologous stromal vascular fraction (SVF) and commercially available bone substitutes (BSs) as new tissue-engineered grafting material (GM) for rhinoplasty. A series of consecutive cases includes four adult patients who underwent rhinoplasty to correct saddle nose deformity (SND) using the new graft technique. SVF was isolated from liposuction aspirate using standard methodology of enzymatic digestion. Two types of BSs were combined with SVF: Bio-Oss granules to create a moldable graft (M-graft), and block-shaped BoneMedik-S to create rigid grafts (R-grafts). The moderate SND was treated using an M-graft. In case of major or complex SND, the nasal dorsum was reconstructed with dorso-columellar L-shaped framework made of R-grafts. The results were evaluated over a period of 6 months to 3 years postoperatively using photogrammetry and FACE-Q appearance appraisal scales. Computerised tomography (CT) scanning of the reconstructed nose and histological analysis of grafted material were also carried out. No complications were observed. The photograms show the restoration of the correct contour of the nose. FACE-Q appraisal scale scores increased significantly, including satisfaction with nose appearance, psychological well-being, and social function. In CT evaluation, there was no substantial resorption or warping of the grafts. Histological findings show osteogenic remodeling of the grafted material. Thus, combining autologous SVF with BSs is a promising strategy for developing rhinoplasty GM. ,Vladimir Karpiuk ... Olga Ponkina [PublishedText] => Published [IsEdit] => 0 [AccountId] => 22 [Zh] => 0 [AuthorsName] => ) [11] => Array ( [ArticleId] => 1322 [Create_Time] => 2024-06-04 [zipUrl] => https://www.explorationpub.com/uploads/zip/202406/20240604070333.zip [xmlUrl] => https://www.explorationpub.com/uploads/Article/A101312/101312.xml [pdfUrl] => https://www.explorationpub.com/uploads/Article/A101312/101312.pdf [coverUrl] => https://www.explorationpub.com/uploads/Article/A101312/101312_cover.png [JournalsId] => 13 [Title] => Biomaterials in dentistry: the analogue/digital transition [Abstract] => [AbstractComplete] => [Names] => Luca Fiorillo [CName] => [Doi] => 10.37349/ebmx.2024.00012 [Published] => June 04, 2024 [Viewed] => 550 [Downloaded] => 30 [Subject] => Editorial [Year] => 2024 [CiteUrl] => https://api.crossref.org/works/10.37349/ebmx.2024.00012 [Inline] => 1 [Type] => 1 [Issue] => 3 [Topic] => 278 [TitleAbbr] => Explor BioMat-X. [Pages] => 2024;1:174–177 [Recommend] => 0 [Keywords] => [DetailTitle] => Innovations in Biomaterials for Dentistry and Oral Surgery [DetailUrl] => https://www.explorationpub.com/Journals/ebmx/Special_Issues/278 [Id] => 101312 [ris] => https://www.explorationpub.com/uploads/Article/A101312/00c120d01776f623fd4d697f0dc77c89.ris [bib] => https://www.explorationpub.com/uploads/Article/A101312/9b0fbeaf4bb538c5d4f45458e2cc0ce1.bib [ens] => [Cited] => 0 [Cited_Time] => [CitethisArticle] => Fiorillo L. Biomaterials in dentistry: the analogue/digital transition. Explor BioMat-X. 2024;1:174–7. https://doi.org/10.37349/ebmx.2024.00012 [Jindex] => 0 [CEmail] => [Ris_Time] => 2024-05-31 01:05:58 [Bib_Time] => 2024-05-31 01:05:58 [KeysWordContens] => Biomaterials in dentistry: the analogue/digital transition,,,Luca Fiorillo [PublishedText] => Published [IsEdit] => 0 [AccountId] => 22 [Zh] => 0 [AuthorsName] => ) [12] => Array ( [ArticleId] => 1382 [Create_Time] => 2024-06-27 [zipUrl] => https://www.explorationpub.com/uploads/zip/202406/20240627031049.zip [xmlUrl] => https://www.explorationpub.com/uploads/Article/A101313/101313.xml [pdfUrl] => https://www.explorationpub.com/uploads/Article/A101313/101313.pdf [coverUrl] => https://www.explorationpub.com/uploads/Article/A101313/101313_cover.png [JournalsId] => 13 [Title] => Bio-materials for intramedullary pin application in canine femur: a comparative analysis [Abstract] => Aim: In this study, the finite elements analysis (FEA) was performed on an intramedullary (IM) pin to be used in the canine femur. The 03 different biomaterials [17-4-precipitated hardened (PH)-s [AbstractComplete] =>In this study, the finite elements analysis (FEA) was performed on an intramedullary (IM) pin to be used in the canine femur. The 03 different biomaterials [17-4-precipitated hardened (PH)-stainless steel (SS), nickel alloys (Ni)-625, titanium alloys (Ti)-6Al-4V] were selected for comparative FEA. In-vitro analysis was also performed in simulated body fluid (SBF) on selected biomaterials for possible application in the canine femur.
FEA was performed on 03 different biomaterials (17-4-PH-SS, Ni-625, and Ti-6Al-4V) based on Von-Mises criteria (at an applied load of 1,500 N, cell type: tetrahedron, grit size: 0.15 mm, number of nodes: 213,989 and elements: 145,012). The distal end of the IM pin was fixed, and the load was applied to the proximal end. In-vitro analysis was performed (on a potentiostat setup) to establish the corrosion rate of various biomaterials (17-4-PH-SS, Ni-625, and Ti-6Al-4V).
The results of FEA show Ni-625 absorbed the maximum Von-Mises stress in the case of tensile and compression loading (104.12 MPa). In the case of torsion loading, the maximum Von-Mises stress was absorbed by 17-4-PH-SS (63.331 MPa). The maximum Von-Mises elastic strain (0.00093473) was observed for Ti-6Al-4V while tensile and compression and minimum deformation (0.013869 mm) in tensile loading.
Based on this study, the maximum safety factor against failure (N) [ratio of 0.2% of yield strength (σy) to the Von-Mises stress (σv)] was observed as 10.75, 11.38, and 15.89, respectively, for tensile, compression, and torsional loading in the case of Ti-6Al-4V. Also, the better biocompatible material for the orthopaedic implant application based on the corrosion result is Ti-6Al-4V due to a lower corrosion rate (2.63211 × 10–10 mm/year) in comparison to 17-4-PH-SS and Ni-625. Overall, the Ti-6Al-4V is a better material than 17-4-PH-SS and Ni-625 for the intended application.